Traders should monitor the upcoming APEX Phase 2 Part A 52-week data readout this month and the head-to-head APG279 vs. Dupixent data in 2H 2026, which could serve as key catalysts if results show competitive dosing or efficacy advantages.
APGE drugs
APGE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $70.92entry
- T+1 · 9mo ago −3.41%α −2.49% · $68.50
- T+5 · 8mo ago +5.68%α +6.88% · $74.94
- T+20 · 8mo ago +11.01%α +18.94% · $78.72
- T+60 · 6mo ago +16.77%α +7.45% · $82.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Apogee Therapeutics reported full-year 2025 financial results with increased R&D and G&A spending driving a wider net loss, while maintaining a strong cash position of $902.9 million that funds operations into 2H 2028. The company highlighted upcoming clinical milestones for its lead asset zumilokibart in atopic dermatitis, asthma, and EoE, including a head-to-head trial against Dupixent with interim data expected in 2H 2026.
Key Facts
- Cash, cash equivalents, and marketable securities totaled $902.9 million as of December 31, 2025, up from $731.1 million in 2024.
- R&D expenses increased to $214.7 million in 2025 from $167.9 million in 2024.
- G&A expenses rose to $70.9 million in 2025 from $49.0 million in 2024.
- Net loss widened to $255.8 million in 2025 from $182.1 million in 2024.
- APEX Phase 2 Part A 52-week data for zumilokibart in atopic dermatitis expected in March 2026.
- Head-to-head Phase 1b trial of APG279 vs. Dupixent in AD to deliver interim data in 2H 2026.
Financial Impact
Increased operating expenses led to a 40% rise in net loss year-over-year, but cash runway extends to 2H 2028.
Risk Factors
- Clinical trial results may not meet expectations, particularly in head-to-head comparison with established therapy Dupixent.
- Increasing operating expenses without near-term revenue could pressure valuation if development timelines extend.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247224 |
Track record
31 reports on APGE
9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers